PL2766040T3 - Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi - Google Patents

Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi

Info

Publication number
PL2766040T3
PL2766040T3 PL12778010T PL12778010T PL2766040T3 PL 2766040 T3 PL2766040 T3 PL 2766040T3 PL 12778010 T PL12778010 T PL 12778010T PL 12778010 T PL12778010 T PL 12778010T PL 2766040 T3 PL2766040 T3 PL 2766040T3
Authority
PL
Poland
Prior art keywords
pertuzumab
trastuzumab
docetaxel
carboplatin
treatment
Prior art date
Application number
PL12778010T
Other languages
English (en)
Inventor
Sreedhara Alavattam
Lukas C Amler
Mark C Benyunes
Emma L Clark
Toledo Pelizon Christina H De
Glover Zephania W Kwong
Lada Mitchell
Jayantha Ratnayake
Graham A Ross
Ru-Amir Walker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47073543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2766040(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2766040T3 publication Critical patent/PL2766040T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Packages (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PL12778010T 2011-10-14 2012-10-11 Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi PL2766040T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161547535P 2011-10-14 2011-10-14
US201161567015P 2011-12-05 2011-12-05
US201261657669P 2012-06-08 2012-06-08
US201261682037P 2012-08-10 2012-08-10
US201261694584P 2012-08-29 2012-08-29
EP12778010.4A EP2766040B1 (en) 2011-10-14 2012-10-11 Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
PCT/US2012/059683 WO2013055874A2 (en) 2011-10-14 2012-10-11 Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab

Publications (1)

Publication Number Publication Date
PL2766040T3 true PL2766040T3 (pl) 2019-11-29

Family

ID=47073543

Family Applications (4)

Application Number Title Priority Date Filing Date
PL24174637.9T PL4403228T3 (pl) 2011-10-14 2012-10-11 Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2
PL12778010T PL2766040T3 (pl) 2011-10-14 2012-10-11 Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi
PL23172847.8T PL4241849T3 (pl) 2011-10-14 2012-10-11 Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2
PL23172794.2T PL4234033T3 (pl) 2011-10-14 2012-10-11 Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL24174637.9T PL4403228T3 (pl) 2011-10-14 2012-10-11 Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL23172847.8T PL4241849T3 (pl) 2011-10-14 2012-10-11 Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2
PL23172794.2T PL4234033T3 (pl) 2011-10-14 2012-10-11 Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2

Country Status (30)

Country Link
US (9) US20130095172A1 (pl)
EP (7) EP3598981A3 (pl)
JP (9) JP2014530235A (pl)
KR (5) KR20240109285A (pl)
CN (8) CN109908341B (pl)
AU (4) AU2012322797B2 (pl)
BR (1) BR112014007521A8 (pl)
CL (1) CL2014000889A1 (pl)
DK (4) DK4234033T3 (pl)
EA (1) EA034390B1 (pl)
ES (4) ES3023516T3 (pl)
FI (3) FI4241849T3 (pl)
HK (1) HK1202242A1 (pl)
HR (1) HRP20191247T1 (pl)
HU (1) HUE044352T2 (pl)
IL (5) IL309917A (pl)
IN (1) IN2014CN02703A (pl)
LT (4) LT4241849T (pl)
MX (2) MX2014004021A (pl)
MY (2) MY194408A (pl)
PE (1) PE20142363A1 (pl)
PH (2) PH12014500733B1 (pl)
PL (4) PL4403228T3 (pl)
PT (4) PT4241849T (pl)
RS (1) RS58944B1 (pl)
SG (3) SG11201401432XA (pl)
SI (4) SI4403228T1 (pl)
UA (2) UA123092C2 (pl)
WO (1) WO2013055874A2 (pl)
ZA (1) ZA201401259B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2742568C (en) 2008-11-03 2017-09-26 Syntarga B.V. Novel cc-1065 analogs and their conjugates
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP3108886B1 (en) 2010-04-21 2020-06-17 Syntarga B.V. Conjugates of cc-1065 analogs and bifunctional linkers
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
BR112015031903A8 (pt) * 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN104726462A (zh) * 2013-12-20 2015-06-24 北京天广实生物技术股份有限公司 抗her2人源化抗体mil41、其制备方法及用途
TR201810856T4 (tr) 2014-01-10 2018-08-27 Synthon Biopharmaceuticals Bv CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul.
RU2686085C2 (ru) * 2014-01-10 2019-04-24 Синтон Байофармасьютикалс Б. В. Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
JP6342517B2 (ja) * 2014-01-10 2018-06-13 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． 改善されたインビボ抗腫瘍活性を示すデュオカルマイシンａｄｃ
WO2016094341A1 (en) * 2014-12-08 2016-06-16 Synta Pharmaceuticals Corp. Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer
AU2016270686B2 (en) * 2015-05-29 2019-12-19 Expression Pathology, Inc. Quantifying Her2 protein for optimal cancer therapy
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
EP3313890A1 (en) 2015-06-24 2018-05-02 H. Hoffnabb-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
KR20220157515A (ko) * 2016-03-15 2022-11-29 씨젠 인크. Liv1-adc와 화학요법제를 사용한 병용 요법
WO2018085513A1 (en) * 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) * 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117752782A (zh) * 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) * 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
KR102267593B1 (ko) * 2018-10-19 2021-06-21 주식회사 프로티나 Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
WO2020150702A1 (en) * 2019-01-18 2020-07-23 University Of Southern California Methods and compositions to improve the safety and efficacy of cellular therapies
EA202193257A1 (ru) * 2019-05-27 2022-03-10 Толмар Интернэшнл Лимитед Композиции ацетата лейпролида и способы их применения для лечения рака молочной железы
AU2020303572A1 (en) 2019-06-28 2022-01-20 Board Of Regents, The University Of Texas System Preparation of preliposomal Annamycin lyophilizate
MX2021015667A (es) * 2019-06-28 2022-04-18 Univ Texas Metodo de reconstitucion de anamicina liposomica.
AU2020381495A1 (en) * 2019-11-15 2022-05-19 Seagen Inc. Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate
WO2021222068A1 (en) * 2020-04-29 2021-11-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
KR20250151568A (ko) * 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
KR20240119103A (ko) * 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587657D1 (de) 1984-01-30 1993-12-23 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA2055441C (en) 1989-05-19 2003-01-07 Robert M. Hudziak Her2 extracellular domain
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
DK1187632T3 (da) 1999-05-14 2009-04-06 Genentech Inc Behandling med anti-ErbB2-antistoffer
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
CN100381172C (zh) 1999-06-25 2008-04-16 吉尼泰克公司 使用抗-ErbB2抗体治疗前列腺癌
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
RU2270029C2 (ru) 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
PT1282443E (pt) 2000-05-19 2009-12-04 Genentech Inc Análise de detecção génica para melhorar a probabilidade de uma resposta eficaz a uma terapia do cancro com um antagonista de erbb
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
JP4731793B2 (ja) 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
WO2003013434A2 (en) 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
EP1300146A1 (en) 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
US20040048525A1 (en) 2002-01-28 2004-03-11 Sagucio Esteban N. Watercycle for wet rider
CA2481515C (en) 2002-04-10 2013-10-01 Genentech, Inc. Anti-her2 antibody variants
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
RU2321396C2 (ru) 2002-05-17 2008-04-10 Авентис Фарма С.А. Применение доцетаксела/доксорубицина/циклофосфамида во вспомогательной терапии рака молочной железы и яичников
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
WO2004030621A2 (en) * 2002-09-30 2004-04-15 The Trustees Of Boston University Method of treating cancer using adenosine and its analogs
HK1078613A1 (zh) 2002-11-21 2006-03-17 Genentech, Inc. 通过抗-erbb2抗体医治非恶性疾病或病患的疗法
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
WO2004098508A2 (en) 2003-04-30 2004-11-18 Napro Biotherapeutics, Inc. Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
WO2005099756A2 (en) 2004-04-08 2005-10-27 Agus David B ErbB ANTAGONISTS FOR PAIN THERAPY
US7691379B2 (en) 2004-04-12 2010-04-06 Medimmune, Llc Anti-IL-9 antibody formulations
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20050280299A1 (en) 2004-06-18 2005-12-22 Alfmeier Corporation Mounting adaptor for seat assembly, and seat assembly having mounting adaptor
KR20110050567A (ko) 2004-07-22 2011-05-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
US20060067930A1 (en) 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008518902A (ja) 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
US20060121044A1 (en) 2004-12-07 2006-06-08 Genentech, Inc. Selecting patients for therapy with a her inhibitor
UA94899C2 (ru) 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
DK1850874T3 (da) 2005-02-23 2013-11-11 Genentech Inc Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
BRPI0712077A2 (pt) 2006-05-01 2012-01-17 Genentech Inc prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa
JP2009538916A (ja) 2006-05-31 2009-11-12 タリオン ファーマシューティカルズ インコーポレーテッド 志賀毒素関連病状を治療するための方法、組成物、およびキット
US7816300B2 (en) 2006-06-14 2010-10-19 Cataler Corporation Catalyst for purifying exhaust gas
BRPI0715829A2 (pt) 2006-08-21 2013-07-23 Hoffmann La Roche terapia de tumor com um anticorpo anti-vegf
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech, Inc Predição de resposta a um inibidor de her
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
CA2687819A1 (en) 2007-06-06 2008-12-11 F.Hoffmann-La Roche Ag Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN101903025A (zh) 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20090203015A1 (en) * 2008-02-13 2009-08-13 Celera Corporation Multiplex assays for hormonal and growth factor receptors, and uses thereof
WO2009111707A1 (en) 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20110256149A1 (en) 2008-10-09 2011-10-20 Medimmune, Llc Antibody formulation
AR074203A1 (es) * 2008-11-22 2010-12-29 Genentech Inc Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
SG176073A1 (en) 2009-05-29 2011-12-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
RU2654068C1 (ru) 2009-09-28 2018-05-16 Ф.Хоффманн-Ля Рош Аг Бензоксазепиновые ингибиторы pi3 и способы применения
WO2011069074A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
MX2013006392A (es) 2010-12-09 2013-12-06 Genentech Inc Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
SI2884979T1 (sl) 2012-08-17 2019-10-30 Hoffmann La Roche Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
CA2990465A1 (en) 2015-07-07 2017-01-12 Genentech, Inc. Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
WO2018085513A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3858333B1 (en) 2017-10-20 2025-11-26 BioNTech SE Preparation and storage of liposomal rna formulations suitable for therapy
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합
WO2022013189A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
WO2022125483A1 (en) 2020-12-11 2022-06-16 Genentech, Inc. Combination therapies for treatment of her2 cancer
TW202400230A (zh) 2022-03-14 2024-01-01 美商建南德克公司 乳癌的組合療法

Also Published As

Publication number Publication date
US20130095172A1 (en) 2013-04-18
CN116271011B (zh) 2023-10-27
EP2766040A2 (en) 2014-08-20
EP4234033A3 (en) 2023-09-20
JP6646785B1 (ja) 2020-02-14
EP4234033B1 (en) 2025-01-29
LT4403228T (lt) 2025-10-27
MX2014004021A (es) 2014-04-30
JP2026028254A (ja) 2026-02-19
KR20170023195A (ko) 2017-03-02
PL4403228T3 (pl) 2025-11-03
PH12019500519A1 (en) 2021-06-14
PT4234033T (pt) 2025-03-20
IL323574A (en) 2025-11-01
SI4234033T1 (sl) 2025-05-30
EP3598981A3 (en) 2020-06-10
FI4241849T3 (fi) 2024-11-12
CN109908341B (zh) 2023-06-27
MY194408A (en) 2022-11-30
EP4234034A3 (en) 2023-09-20
JP2020033353A (ja) 2020-03-05
PT4241849T (pt) 2024-10-30
UA116095C2 (uk) 2018-02-12
IL309917A (en) 2024-03-01
ES3023516T3 (en) 2025-06-02
CN114984205A (zh) 2022-09-02
EP4403228A3 (en) 2024-10-23
AU2016204962A1 (en) 2016-08-04
EA034390B1 (ru) 2020-02-03
EP4241849B1 (en) 2024-09-18
KR102502545B1 (ko) 2023-02-21
IL231350B1 (en) 2023-04-01
EP4234033A2 (en) 2023-08-30
US20160175438A1 (en) 2016-06-23
PH12014500733B1 (en) 2019-07-17
KR20230073340A (ko) 2023-05-25
KR20140075725A (ko) 2014-06-19
SI2766040T1 (sl) 2019-08-30
NZ750877A (en) 2020-09-25
WO2013055874A3 (en) 2013-06-20
LT4234033T (lt) 2025-04-10
CN104334189A (zh) 2015-02-04
KR102770098B1 (ko) 2025-02-20
EA201490779A1 (ru) 2015-11-30
CN116808199A (zh) 2023-09-29
SI4403228T1 (sl) 2025-11-28
EP4241849A3 (en) 2023-09-20
JP7352760B2 (ja) 2023-09-28
CN116236569A (zh) 2023-06-09
JP2023109780A (ja) 2023-08-08
KR20240109285A (ko) 2024-07-10
US20230277663A1 (en) 2023-09-07
DK4241849T3 (da) 2024-11-18
EP2766040B1 (en) 2019-05-15
AU2018203970B2 (en) 2019-11-21
DK4403228T3 (da) 2025-10-13
US20190117769A1 (en) 2019-04-25
AU2019261666A1 (en) 2019-11-28
US20220362379A1 (en) 2022-11-17
MY172326A (en) 2019-11-21
IL286921A (en) 2021-10-31
US12527867B2 (en) 2026-01-20
UA123092C2 (uk) 2021-02-17
ES3045013T3 (en) 2025-11-27
CN116271013A (zh) 2023-06-23
AU2012322797A1 (en) 2014-03-20
IN2014CN02703A (pl) 2015-07-03
CN116271011A (zh) 2023-06-23
US20200376120A1 (en) 2020-12-03
AU2018203970A1 (en) 2018-06-21
EP3598981A2 (en) 2020-01-29
AU2012322797B2 (en) 2016-04-21
FI4403228T3 (fi) 2025-10-15
JP2014530235A (ja) 2014-11-17
IL231350A0 (en) 2014-04-30
AU2019261666B2 (en) 2021-08-05
JP2022062010A (ja) 2022-04-19
LT4241849T (lt) 2024-11-25
DK4234033T3 (da) 2025-03-31
PH12014500733A1 (en) 2014-06-30
PL4234033T3 (pl) 2025-04-28
CN109908341A (zh) 2019-06-21
ES2736005T3 (es) 2019-12-23
PT2766040T (pt) 2019-07-11
HRP20191247T1 (hr) 2019-10-18
JP2024009803A (ja) 2024-01-23
SG10202110077QA (en) 2021-10-28
SG10201606756PA (en) 2016-10-28
SI4241849T1 (sl) 2025-01-31
BR112014007521A2 (pt) 2017-12-12
SG11201401432XA (en) 2014-05-29
AU2016204962B2 (en) 2018-03-08
PE20142363A1 (es) 2015-01-30
EP4635572A2 (en) 2025-10-22
JP2020090507A (ja) 2020-06-11
PL4241849T3 (pl) 2025-01-13
EP4241849A2 (en) 2023-09-13
BR112014007521A8 (pt) 2018-04-10
FI4234033T3 (fi) 2025-03-31
WO2013055874A2 (en) 2013-04-18
JP2017222663A (ja) 2017-12-21
US20210015919A1 (en) 2021-01-21
HUE044352T2 (hu) 2019-10-28
KR20230028585A (ko) 2023-02-28
US20200206348A1 (en) 2020-07-02
MX2019009153A (es) 2019-10-14
ES2993341T3 (en) 2024-12-27
KR102099991B1 (ko) 2020-04-14
JP2023109779A (ja) 2023-08-08
RS58944B1 (sr) 2019-08-30
JP7303957B1 (ja) 2023-07-05
EP4403228B1 (en) 2025-07-16
EP4234034A2 (en) 2023-08-30
LT2766040T (lt) 2019-08-12
EP4403228A2 (en) 2024-07-24
NZ621367A (en) 2016-04-29
AU2012322797A8 (en) 2014-06-26
PT4403228T (pt) 2025-10-07
DK2766040T3 (da) 2019-07-22
HK1202242A1 (en) 2015-09-25
IL301603A (en) 2023-05-01
IL231350B2 (en) 2023-08-01
ZA201401259B (en) 2019-01-30
US20230277664A1 (en) 2023-09-07
CL2014000889A1 (es) 2014-07-25
KR102679155B1 (ko) 2024-06-28
CN117018187A (zh) 2023-11-10

Similar Documents

Publication Publication Date Title
PL2766040T3 (pl) Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi
PL2768493T3 (pl) Fitokannabinoidy do stosowania w leczeniu raka piersi
IL264057B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
IL239007B (en) Eribulin for use in the treatment of breast cancer
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
EA201400178A1 (ru) Лечение рака молочной железы
BR112014007603A2 (pt) métodos de tratamento do câncer
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
NZ601065A (en) Wnt antagonists and methods of treatment and screening
LT2707030T (lt) Vėžio gydymas
BR112014012880A2 (pt) tratamento imunogênico do câncer
EA201201474A1 (ru) Способы лечения рака молочной железы
HUE046667T2 (hu) Rák kombinatív kezelése
IL253947A0 (en) Methods of treating breast cancer with taxane therapy
BR112014012495A2 (pt) método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
PL2838998T3 (pl) EGFR i ROS1 w nowotworze
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów
IL231757A0 (en) Treatment of malignant and nonmalignant diseases with ras antagonists
HRP20180685T1 (hr) Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo
PH12013502663A1 (en) Dosage administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
IL230575B (en) Synthetic lethality and the treatment of cancer
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных
EP2699696A4 (en) MOLECULAR UNTERTYPING, FORECASTING AND TREATMENT OF PROSTATE CANCER
EA201301080A1 (ru) Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания
TH1201006302B (th) ฟอสฟาพลาตินและการใช้เพื่อรักษาโรคมะเร็ง (Phosphaplatins and their use for treatment of cancers)